Articles
	12/22/2004	Winning The Drug-Approval Game: 2004 The odds of winning coveted FDA approval have always been outrageously low, yet many firms possess the skill and luck that allow them to triumph in the end. And 2004 was no exception: Biotechs brought 23 new drugs to market, many of which are first-in-kind therapies.
	11/23/2004	Striking Down Parkinson’s New approaches for treating the debilitating symptoms of Parkinson’s disease – some of them aimed at slowing disease progression or even regenerating damaged nerves – may provide a major victory for patients and doctors alike.
	10/20/2004	Biomarkers: The Pendulum Finally Swings Biomarkers are already used routinely in R&D programs, but few firms have been willing to spend the money to incorporate them into clinical studies. That is, until the Vioxx disaster, which showed just how expensive it can be to not do so.
	9/14/2004	The Ties That (Don’t) Bind Innovation, creativity, a collegial environment – these are all keys to Roche’s laissez faire approach to its biotech partnerships. Respecting autonomy and remaining flexible worked with Genentech, and it’s still working today.
	8/09/2004	New Kids On The Block Members of the IPO Class of 2003-2004 burst upon the public scene with finely honed skills that set them aside from the previous generation. They’ve got drugs in the clinic already --- among them new anti-infectives that are set to soar.
	7/09/2004	BioShield And Beyond Biotech firms have responded rapidly to the government’s call for new vaccines and drugs for biodefense, and Project BioShield guarantees them a buyer in the end. But where do they find the money for R&D and clinical trials?
	6/04/2004	The Tech Transfer Pie Nearly all academic institutions now out-license their IP for commercial development, but some are savvier than others when it comes to maximizing the rewards they reap from their inventions.
	5/07/2004	The Eyes Have It Until recently, few firms recognized the huge unmet medical need for new therapies to treat AMD and diabetic retinopathy – dreadful diseases that blind millions of people. But perception has changed radically – and dozens of drugs are now in the clinic.
	4/02/2004	The Licensing-Go-Round In-licensing, out-licensing, returned rights, terminated deals, re-partnering -- they’re all part of the dizzying business of drug development. But some product candidates go around so often that it’s hard to remember where they started.
	3/05/2004	Armed Antibodies It’s become quite clear that most monoclonals are not very good at killing cancer cells on their own. That’s why there’s been a resurgence of interest in antibodies that deliver a lethal payload — be it a drug, a toxin or a radionuclide.
	2/06/2004	The New Product Parade Early on, biotech firms marched to a different drummer than big pharmas, focusing on protein therapies rather than small molecule drugs. Today, however, they’re in step, as the types of new biotech medicines approved in 2003 clearly show.
	1/09/2004	Financing Finally Flows The biotech industry’s pent-up demand for life-sustaining cash was finally satisfied in 2003 with an eruption of $16.7 billion in new financing -- making it the second biggest annual haul in the sector’s history.
top
		Buzz
	11/10/2004	Wake Up Call For Vaccines
	10/06/2004	Ahead Of The Curve
	8/27/2004	2004 Product Sales Will Easily Clear The $50B Mark
	7/02/2004	A Hard Act To Follow
	6/02/2004	BIO’s Feldbaum: It’s Been A Wild Ride
	4/22/2004	Full Steam Ahead
	3/10/2004	Robust Sales Drive Sector
	2/09/2004	FDA’s New Initiatives Taking Off
	1/06/2004	IPO Monitor
top
		Data Mining
	9/24/2004	Second Quarter 2004 Alliance Scorecard – Earned Revenues Top $1.4B YTD
	7/30/2004	First Quarter 2004 Alliance Scorecard – Chemistry, Cancer Coming On Strong
top
		Focal Point
	12/16/2004	Giant Steps In Genetics
	10/27/2004	Late-Stage Deals Have Lots of Appeal
	9/16/2004	Agbiotech Roulette
	7/15/2004	U.K., U.S. Cooperate, Compete On Anthrax Vaccine
	6/17/2004	A Peek Into Biotech’s Future
	5/04/2004	The Next Tidal Wave?
	3/19/2004	Sanofi: Leader Of The Pack?
	2/12/2004	Partners Bid Up Mid-Stage Deals
	1/21/2004	IPO Step-Ups & Valuations: Then & Now
top
		School Zone
	12/03/2004	Universities Reap Bayh-Dole’s Benefits
	2/27/2004	Alliances: La Crème de la Crème
top
		Signals vs Noise
	10/08/2004	Financial Snapshot For September 2004: In Need Of A Boost
	7/07/2004	Financial Snapshot For June 2004: Lackluster Performance
	4/14/2004	Financial Snapshot For March 2004: Looking Good
	1/16/2004	Financial Snapshot For December 2003: Bulls Charge Ahead
top
		Turn Signals
	10/29/2004	BECIF: New Faces, Old Favorites
	10/01/2004	Foundations Spark Research on Rare Diseases
	8/17/2004	Turn The Page
	6/28/2004	Dramatic Turns In Drug Development
	5/17/2004	How To Land A Big Fish
	3/24/2004	Allicense 2004: Come Meet The Winner
	2/23/2004	Hunting For Crown Jewels
	1/26/2004	JPMorgan Conference 2004, Orange Bags And All
top
		Trivia
	12/29/2004	Cherry Pie
	12/22/2004	Epigenetics
	12/15/2004	Amyris
	12/08/2004	Sunlight
	12/01/2004	Typhoid fever
	11/24/2004	Spanish Gene
	11/17/2004	Poppy
	11/10/2004	Origins
	11/03/2004	Incyte IPO
	10/27/2004	Repetitive DNA
	10/20/2004	Conan
	10/13/2004	Muscle
	10/06/2004	Intarcia
	9/29/2004	Essential
	9/22/2004	Pets
	9/15/2004	Pathema
	9/08/2004	Cotton
	9/01/2004	Sirtuin
	8/25/2004	CAG
	8/18/2004	Teeth
	8/11/2004	Worm
	8/04/2004	Amish Babies
	7/28/2004	Well, Well
	7/21/2004	Cellumen
	7/14/2004	Pre-GNE
	7/07/2004	Greek To Me
	6/30/2004	Asses
	6/23/2004	Fat Mice
	6/16/2004	Knighthood
	6/09/2004	First Convention
	6/02/2004	Doggies
	5/26/2004	Targacept
	5/19/2004	Receptor
	5/12/2004	Aspreva
	5/05/2004	Heavy Chain
	4/28/2004	HDL
	4/21/2004	Splits
	4/14/2004	Rats
	4/07/2004	Chromosomes
	3/31/2004	Jazz
	3/24/2004	Cell Genesys
	3/17/2004	Inhibitor
	3/10/2004	Sargasso
	3/03/2004	Xoma
	2/25/2004	Double Helix
	2/18/2004	Big Deal
top